Not currently recruiting at UCSF

A Maintenance Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis

a study on Inflammatory Bowel Disease

Summary

for people ages 18-80 (full criteria)
at San Francisco, California and other locations
study started
estimated completion:

Description

Summary

The purpose of this study is to evaluate the efficacy and safety of mirikizumab as maintenance therapy in participants who completed prior 12-week induction study AMAN (NCT03518086).

Official Title

A Phase 3, Multicenter, Randomized, Double-Blind, Parallel-Arm, Placebo-Controlled Maintenance Study of Mirikizumab in Patients With Moderately to Severely Active Ulcerative Colitis (LUCENT 2)

Keywords

Ulcerative Colitis Interleukin-23 (IL-23) IL-23p19 Inflammatory Bowel Disease Colitis Ulcer Colitis, Ulcerative Mirikizumab Mirikizumab Dose #1 Mirikizumab Dose #2

Eligibility

You can join if…

Open to people ages 18-80

  • Have completed Study AMAN (NCT03518086), with at least 1 study drug administration and without early termination of study drug.
  • Are willing and able to complete the scheduled study assessments, including endoscopy and daily diary entry.
  • If female, must meet the contraception requirements.

You CAN'T join if...

  • Participants diagnosed with Crohn's disease or inflammatory bowel disease-unclassified(indeterminate colitis) during the induction study AMAN (NCT03518086).
  • Participants with a bowel resection or other surgery for the treatment of UC during the previous induction study AMAN (NCT03518086), or are likely to require surgery for the treatment of UC during study AMBG.
  • Participants with evidence of colonic dysplasia or have been diagnosed with cancer of the gastrointestinal tract during study AMAN (NCT03518086).
  • Participants diagnosed with clinically important infection including, but not limited to, hepatitis B, hepatitis C, HIV/AIDS, and active tuberculosis (TB) during the induction study AMAN (NCT03518086).
  • Participants who initiate a new prohibited medication during the induction study AMAN(NCT03518086).
  • Participants with certain laboratory abnormalities prior to start of AMBG that would require permanent discontinuation from study drug.

Locations

  • University of California, San Francisco not yet accepting patients
    San Francisco California 94158 United States
  • Care Access Research not yet accepting patients
    San Pablo California 94806 United States

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
Eli Lilly and Company
ID
NCT03524092
Phase
Phase 3
Study Type
Interventional
Last Updated